 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...1516171819202122232425...3839» |
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Trial completion date, Trial primary completion date: OTIS Cimzia Pregnancy Registry (clinicaltrials.gov) - Apr 5, 2021
P=N/A, N=925, Recruiting, Sponsor: University of California, San Diego
N=500 --> 925 | Trial completion date: Dec 2022 --> Oct 2026 | Trial primary completion date: Jan 2020 --> Sep 2023
- | Retrospective data, Journal: Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. (Pubmed Central) - Apr 1, 2021
N=500 --> 925 | Trial completion date: Dec 2022 --> Oct 2026 | Trial primary completion date: Jan 2020 --> Sep 2023 Ixekizumab, risankizumab, and brodalumab had the highest short-term efficacy, and risankizumab had the highest long-term efficacy.
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Clinical, Journal: A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients. (Pubmed Central) - Mar 30, 2021
Objectives: To assess whether the histopathological features of the synovium before starting treatment with the TNFi certolizumab-pegol could predict clinical outcome and examine the modulation of histopathology by treatment...Finally, we confirmed a significant fall in the number of CD68+ sublining macrophages post-treatment in responders and a correlation between the reduction in the CD20+ B-cells score and the improvement in the DAS28 at 12-weeks. The analysis of the synovial histopathology may be a helpful tool to identify among clinically indistinguishable patients those with lower probability of response to TNFα-blockade.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis (clinicaltrials.gov) - Mar 29, 2021
P1, N=30, Recruiting, Sponsor: UCB Biopharma SRL
The analysis of the synovial histopathology may be a helpful tool to identify among clinically indistinguishable patients those with lower probability of response to TNFα-blockade. Not yet recruiting --> Recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] Biopsy Confirmed Subacute Thyroiditis Associated With COVID-19 () - Mar 27, 2021 - Abstract #ENDO2021ENDO_3437;
On 06/03/2020, a 28 year old woman with previous history of ankylosing spondylitis managed with certolizumab pegmol, presented with fatigue, headache, odynophagia, and fever (38.1°C)...Treatment was initiated with prednisone 10 mg PO QD, propranolol 20 mg PO BID for 2 weeks, and acetaminophen 1 gr PO TID PRN...Replacement therapy with levothyroxine 88 mcg per day was initiated...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
- | Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Retrospective data, Journal: Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis. (Pubmed Central) - Mar 23, 2021
Egger's test suggested no possibility of publication bias. This meta-analysis shows that TNFi are effective to improve MRI inflammation in patients with axial spondyloarthritis and the treatment effectiveness is not affected by diagnostic category and TNFi types.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
NICE: Not sure exactly - we have meds approved by NICE ,cimzia is only approved for RA, AS, plaque psoriasis I think....not Crohns... (Twitter) - Mar 18, 2021
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: CIMcare: A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (clinicaltrials.gov) - Mar 16, 2021
P3, N=150, Recruiting, Sponsor: UCB Biopharma SRL
This meta-analysis shows that TNFi are effective to improve MRI inflammation in patients with axial spondyloarthritis and the treatment effectiveness is not affected by diagnostic category and TNFi types. Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Sep 2024
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: CIMREAL: A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (clinicaltrials.gov) - Mar 16, 2021
P=N/A, N=650, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial completion date: Oct 2022 --> Jan 2023 | Trial primary completion date: Oct 2022 --> Jan 2023
- || Clinical, Retrospective data, Review, Journal: Efficacy and Safety of Anti-TNFα Therapy for Uveitis Associated with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 16, 2021
The effectiveness of IFX is higher than ETA with no statistical difference. GLM and CZP may be proxies for ADA but the evidence is limited.
- [VIRTUAL] GREATER HAZARD OF INFECTION WITH ANTI-TUMOR NECROSIS FACTOR (ATNF) USE COMPARED TO NO ATNF USE IN INFLAMMATORY BOWEL DISEASE: A LARGE RETROSPECTIVE USA CLAIMS DATABASE ANALYSIS (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3467;
After matching, there were no significant differences between groups (sdiff<0.2) with the exception of immunomodulator use, region, and plan type, which were adjusted in the model. Mean (SD) age was 41.54 (14.59), 49.8% female, with mean (SD) follow-up time of 0.88 (0.77) years.
- [VIRTUAL] DOSE ESCALATION AND TREATMENT PERSISTENCE OF INFLAMMATORY BOWEL DISEASE BIOLOGIC THERAPIES IN A LARGE USA RETROSPECTIVE CLAIMS DATABASE (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3443;
In the UC cohort overall mean age was 42±14.7 years; male 53.5% at index episode (n=4,812). For 1st line (1L) biologic CD patients (Figure 1), only a minority persisted (defined as not discontinuing, switching, or being lost to enrolment) on treatment in the 1st year (ADA 38.3%, CER 38.3%, IFX 40.6%, VDZ 42.4%).
- [VIRTUAL] TREATMENT PATTERNS IN BIOLOGIC-EXPERIENCED CROHN’S DISEASE PATIENTS USING THREE LARGE COMMERCIAL CLAIMS DATABASES IN THE UNITED STATES (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3245;
Adherence and dose reduction followed a similar trend. Further research is needed to examine treatment patterns after adjusting for confounders and baseline differences.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] NON-MELANOMA SKIN CANCER: INCIDENCE AND POTENTIAL RISK FACTORS IN CROHN'S DISEASE PATIENTS IN THE SECURE REGISTRY (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3103;
The primary goal was to collect and compare safety data from pts with moderate to severe CD receiving certolizumab pegol (CZP) to data from pts receiving other treatments, including biologics and immunosuppressives (comparator cohort)...These registry data suggest that the increased incidence of NMSC in CD pts may be related to the use of immunosuppressives, but not TNF antagonists. A limitation was the small number of NMSC cases, despite relatively high incidence in the SECURE Registry.
- [VIRTUAL] UTILIZATION OF BIOLOGIC MEDICATIONS AND IMMUNOMODULATORS AMONG PATIENTS WITH HEART FAILURE AND CROHN’S DISEASE IN THE UNITED STATES BETWEEN 2015 AND 2020: A POPULATION-BASED STUDY (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3091;
This population suffers a higher rate of colectomy and are less likely to use biologics and immunomodulators. While studies have shown complications related to specific TNF inhibitors in HF, this study shows that providers may be wary to prescribe any biologic or immunomodulators to patients with HF.
- [VIRTUAL] OPPORTUNISTIC INFECTIONS ARE MORE COMMON IN CHRONIC PANCREATITIS: A LARGE POPULATION-BASED STUDY (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_2621;
Despite excluding other chronic inflammatory and immunocompromised conditions and after adjusting for confounders, patients with CP were still more likely to develop OI overall with bacterial OI having the highest risk. Malnutrition and total parenteral nutrition carried the highest risk association of OI in CP.
- [VIRTUAL] UTILIZATION OF COLONOSCOPY FOLLOWING TREATMENT INITIATION IN COMMERCIALLY-INSURED US PATIENTS WITH INFLAMMATORY BOWEL DISEASE, 2013-2018 (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_1589;
Only 16-18% of newly-treated IBD patients underwent colonoscopy within 90-450 days of initiating a new treatment. These findings suggest poor uptake of treat-to-target disease monitoring in real world clinical practice.
- | tofacitinib / Generic mfg.
New trial: STAR-RA-Cancer: Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints (clinicaltrials.gov) - Mar 15, 2021
P, N=105711, Active, not recruiting, Sponsor: Brigham and Women's Hospital
- || PK/PD data, Journal: Metabolic, pharmacokinetic and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. (Pubmed Central) - Mar 13, 2021
Careful patient selection and close monitoring during treatment are mandatory to provide safe and effective use of the TNF-α inhibitor. Familiarity with biologic agents is crucial because of these agents could became a consolidated treatment option in the clinician's therapeutic approaches.
- ||| [publication CRCT] https://t.co/JO5cPQLLy5 @Melasphinx ; @Caregraduate ; @CCR_AACR @ToulouseCancer @FRM_officiel @BMSFrance @CanceropoleGSO #TNF, #antiTNF, #PD1, #CTLA4, #melanoma, #nivolumab, #ipilimumab, #infliximab, #certolizumab (Twitter) - Mar 11, 2021
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
I've had >major gastro autoimmune disorder< for 30 years. About 15 years ago I was prescribed Cimzia. All it took was a phone call and a form, and my $10K monthly prescription bill became $0. I've never understood the hate. (Twitter) - Mar 10, 2021
- | Journal: Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease. (Pubmed Central) - Mar 9, 2021
Among patients with IBD, dose escalation occurred with all TIMs examined with varying degrees of prevalence and magnitude. Real-world utilization patterns of TIMs indicate that dose escalation is an important part of the clinical management of IBD and needs to be considered when evaluating the cost-effectiveness of IBD treatments.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: Study of Cimzia for the Treatment of Ulcerative Colitis (clinicaltrials.gov) - Mar 3, 2021
P2, N=25, Active, not recruiting, Sponsor: University of Washington
Real-world utilization patterns of TIMs indicate that dose escalation is an important part of the clinical management of IBD and needs to be considered when evaluating the cost-effectiveness of IBD treatments. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- || Review, Journal: New Treatment Addressing the Pathogenesis of Psoriasis. (Pubmed Central) - Mar 3, 2021
Based on these findings, we summarize currently available oral treatments and biologics. Furthermore, we describe a new treatment option including Janus kinase inhibitor, tyrosine kinase 2 inhibitor, modulator of sphingosine 1-phosphate receptor 1, and Rho-associated kinase 2 inhibitor.
- | Trial completion date: Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity (clinicaltrials.gov) - Mar 2, 2021
P4, N=25, Active, not recruiting, Sponsor: Karolinska Institutet
Furthermore, we describe a new treatment option including Janus kinase inhibitor, tyrosine kinase 2 inhibitor, modulator of sphingosine 1-phosphate receptor 1, and Rho-associated kinase 2 inhibitor. Trial completion date: Sep 2020 --> Dec 2021
- || Clinical, Journal: Surveillance of Psoriatic Patients on Biologic Treatment During The COVID-19 Pandemic: A Single-Center Experience. (Pubmed Central) - Feb 27, 2021
Five patients reported suspicious symptoms, but only one had PCR-confirmed COVID-19. Our findings suggest that biologic treatment for moderate-to-severe psoriasis would not pose an additional risk for COVID-19 infection and its life-threatening complications, even in the presence of a high frequency of cardiometabolic comorbidities, provided that all patients are informed and necessary pandemic-directed precautions are well adopted by the patients.
- | tofacitinib / Generic mfg.
New trial: Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints (clinicaltrials.gov) - Feb 25, 2021
P, N=105711, Active, not recruiting, Sponsor: Brigham and Women's Hospital
- || Clinical, Journal: Psoriasis Associated with Tumor Necrosis Factor-Alpha Inhibitors in Children with Inflammatory Diseases. (Pubmed Central) - Feb 24, 2021
Our findings suggest that biologic treatment for moderate-to-severe psoriasis would not pose an additional risk for COVID-19 infection and its life-threatening complications, even in the presence of a high frequency of cardiometabolic comorbidities, provided that all patients are informed and necessary pandemic-directed precautions are well adopted by the patients. Children with IBD, JIA, and CNO had an increased rate of psoriasis compared to the general pediatric population, with the highest rate in those with TNFi exposure.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study () - Feb 21, 2021 - Abstract #CRAAHPA2021CRA-AHPA_322;
P4
During 96 weeks’ CZP treatment, there was a significant reduction of 82% in the AAU flare rate compared to pre-baseline. There were also substantial improvements in patients’ axSpA disease activity.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] Rates of Disease Flares and Adverse Pregnancy Outcomes Among Pregnant Women Treated With Tumour Necrosis Factor Inhibitors (TNFi) for Inflammatory Arthritis () - Feb 21, 2021 - Abstract #CRAAHPA2021CRA-AHPA_149;
Women treated with TNFi also had confounding refractory disease and obstetrical risk factors which possibly contributed to an increased risk for adverse pregnancy outcomes, reinforcing the need for collaboration between rheumatologists and obstetricians for optimal care. Further research should control for obstetrical risk factors in pregnant women with IA to elucidate the independent impact of TNFi treatment on risk for adverse pregnancy outcomes.
- [VIRTUAL] Discontinuation Rate of Tofacitinib is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Results From the Ontario Best Practices Research Initiative (OBRI) () - Feb 21, 2021 - Abstract #CRAAHPA2021CRA-AHPA_80;
In this real world data study, we found that TNFi and TOFA retention is similar in patients with RA. Merging data with other RA registries in Canada is proposed to increase study power and to provide more robust results.
- ||| Clinical, Clinical guideline, Review, Journal: The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. (Pubmed Central) - Feb 20, 2021
TNF-α inhibitors seem to be the safest and most researched biological drugs used in psoriasis treatment of patients planning to conceive, during pregnancy or lactation. Given its non-existent or minimal placental permeability, most likely the safest alternative is certolizumab pegol.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
P2/3 data, Journal: Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study. (Pubmed Central) - Feb 20, 2021
P2/3
Given its non-existent or minimal placental permeability, most likely the safest alternative is certolizumab pegol. CZP dosed at 400 mg or 200 mg Q2W was associated with improved PSO signs and symptoms.
- | Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Journal: Improvement of Certolizumab Fab' properties by PASylation technology. (Pubmed Central) - Feb 18, 2021
Pharmacokinetic studies also showed prolonged terminal half-life and improved pharmacokinetic parameters in PASylated recombinant protein in comparison to the PEGylated and Fab' control molecules. The results reconfirmed the efficiency of PASylation approach as a potential alternative method in increasing the half-life of pharmaceutical proteins.
- | Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Journal: Simultaneous bilateral aqueous misdirection following certolizumab therapy for rheumatoid arthritis. (Pubmed Central) - Feb 17, 2021
We present a case of simultaneous bilateral aqueous misdirection following the administration of certolizumab in a 41-year-old women with rheumatoid arthritis and no known risk factors. To our knowledge, aqueous misdirection has not previously been associated with the use of tumour necrosis factor-alpha inhibitors.
- | Retrospective data, Journal: Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study. (Pubmed Central) - Feb 16, 2021
In biologic-naïve patients treated with SC-TNFi for IA, cyclers significantly increased their non-treatment HCRU costs 12 months after switching treatment while persistent patients lowered their costs during the same time period. As these findings indicate that differences in treatment persistence may have an impact on costs, further research utilizing more comprehensive data sources in alternate settings is warranted.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
What is the best antI TNF For non radiographic SPA ? What a bout specifically certolizumab in radiographic SPA? (Twitter) - Feb 11, 2021
- |||| Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
C-View interim analysis: certolizumab effective in anterior uveitis. While in Swedish Registry SEC may be less effective in control of AU vs TNFi. Drs. Ogdie and @JointMD @RWCSmtg @RheumNow #RWCS2021 #RWCS (Twitter) - Feb 11, 2021
- | Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Journal: Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. (Pubmed Central) - Feb 11, 2021
In a mixed cohort of RA and AS patients, TNF inhibition improved or stabilized vascular pathophysiology. Inflammation may be associated with FMD, while, among others, cNR may influence vascular function.
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Clinical, Journal: Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. (Pubmed Central) - Feb 11, 2021
Inflammation may be associated with FMD, while, among others, cNR may influence vascular function. Certolizumab pegol is effective and safe in women with uveitis during pregnancy.
- | Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Journal: Experience of a Performance-Based Risk-Sharing Arrangement for the Treatment of Rheumatoid Arthritis With Certolizumab Pegol. (Pubmed Central) - Feb 10, 2021
Certolizumab pegol is effective and safe in women with uveitis during pregnancy. The performance-based risk-sharing arrangement proved to be a useful tool to optimize the resources of the healthcare payer and contributed to the collection of scientific evidence in real-life patients.
- || Clinical, Journal, HEOR: Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. (Pubmed Central) - Feb 9, 2021
The performance-based risk-sharing arrangement proved to be a useful tool to optimize the resources of the healthcare payer and contributed to the collection of scientific evidence in real-life patients. The findings of no significant differences in outcomes between first-line TNF versus first-line non-TNF groups support RA guidelines, which recommend individualised care based on clinical judgement and consideration of patient preferences.
- [VIRTUAL] UNDERSTANDING REAL-WORLD BIOLOGIC MAINTENANCE DOSING PATTERNS AMONG PEDIATRIC ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS (Epidemiology) - Feb 5, 2021 - Abstract #CCCongress2021CCCongress_303;
TNF inhibitors remain the most commonly used class of biologic, but the doses being used are double the standard dosing guidelines. There is little evidence of dose reduction over time among pediatric UC and CD patients in the ICN registry.
- [VIRTUAL] TREATMENT PATTERNS OF NEWLY DIAGNOSED PEDIATRIC ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS IN THE IMPROVECARENOW REGISTRY (Epidemiology) - Feb 5, 2021 - Abstract #CCCongress2021CCCongress_302;
Conclusion These results highlight the current treatment patterns of pediatric UC and CD patients in the United States. At the initial ICN visit, the 46% of UC and 40% of CD patients were receiving corticosteroids, however, at 1-year and 3-years after initial visit, over 30% of UC patients and over 60% of CD patients were receiving TNF inhibitors with considerably reduced corticosteroid use.
- [VIRTUAL] IDENTIFYING INADEQUATE RESPONSE AMONG CROHN’S DISEASE PATIENTS ON A BIOLOGIC IN A REAL-WORLD ADMINISTRATIVE CLAIMS DATABASE (Epidemiology) - Feb 5, 2021 - Abstract #CCCongress2021CCCongress_297;
This modified claims-based algorithm for CD appears useful to classify inadequate responders in health plan claims data. Additional research is needed to further validate this algorithm in a clinical setting.
- [VIRTUAL] THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS (Natural History and Outcomes) - Feb 5, 2021 - Abstract #CCCongress2021CCCongress_243;
Approximately a quarter of patients experienced adverse events that were mainly due to infections. Larger studies are needed to elucidate the relative safety of different biologic agents and small molecules in IBD patients with cirrhosis.
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Clinical, Journal: Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches. (Pubmed Central) - Feb 5, 2021
Monoclonal antibody therapies have revolutionized the treatment of chronic inflammatory disorders such as psoriasis and hidradenitis suppurativa. Given the good clinical response to anti-IL-17 and anti-tumor necrosis factor agents in patients undergoing psoriasis and hidradenitis treatment, investigations on this direction could represent the starting point in new therapeutic approach for revolutionary treatment in these difficult-to-treat diseases.
- [VIRTUAL] INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_3082;
P3
ISRs were often mild or manageable, indicating these events are likely not a barrier to treatment. Comparable trends for reported ISRs have been observed with drugs delivered similarly to pegcetacoplan; management strategies for ISRs with these drugs may potentially be useful for reactions observed with pegcetacoplan.
- [VIRTUAL] INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_3081;
P3
ISRs were often mild or manageable, indicating these events are likely not a barrier to treatment. Comparable trends for reported ISRs have been observed with drugs delivered similarly to pegcetacoplan; management strategies for ISRs with these drugs may potentially be useful for reactions observed with pegcetacoplan.
- [VIRTUAL] INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_3080;
P3
ISRs were often mild or manageable, indicating these events are likely not a barrier to treatment. Comparable trends for reported ISRs have been observed with drugs delivered similarly to pegcetacoplan; management strategies for ISRs with these drugs may potentially be useful for reactions observed with pegcetacoplan.